BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 36200799)

  • 21. Immunohistochemistry is highly sensitive and specific for detection of BRAF V600E mutation in pleomorphic xanthoastrocytoma.
    Ida CM; Vrana JA; Rodriguez FJ; Jentoft ME; Caron AA; Jenkins SM; Giannini C
    Acta Neuropathol Commun; 2013 May; 1():20. PubMed ID: 24252190
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Detection of the BRAF V600E mutation in colon carcinoma: critical evaluation of the imunohistochemical approach.
    Lasota J; Kowalik A; Wasag B; Wang ZF; Felisiak-Golabek A; Coates T; Kopczynski J; Gozdz S; Miettinen M
    Am J Surg Pathol; 2014 Sep; 38(9):1235-41. PubMed ID: 24832158
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Molecular features of metanephric adenoma and their values in differential diagnosis].
    Wang X; Shi SS; Yang WR; Ye SB; Li R; Ma HH; Zhang RS; Lu ZF; Zhou XJ; Rao Q
    Zhonghua Bing Li Xue Za Zhi; 2017 Jan; 46(1):38-42. PubMed ID: 28072975
    [No Abstract]   [Full Text] [Related]  

  • 24. VE1 immunohistochemistry is an adjunct tool for detection of BRAF
    Rashid FA; Tabassum S; Khan MS; Ansari HR; Asif M; Sheikh AK; Sameer Aga S
    J Clin Lab Anal; 2021 Feb; 35(2):e23628. PubMed ID: 33305405
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Analysis of immunocytochemical and molecular BRAF expression in thyroid carcinomas: a cytohistologic institutional experience.
    Rossi ED; Martini M; Capodimonti S; Cenci T; Straccia P; Angrisani B; Ricci C; Lanza P; Lombardi CP; Pontecorvi A; Larocca LM; Fadda G
    Cancer Cytopathol; 2014 Jul; 122(7):527-35. PubMed ID: 24639117
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Detection of the BRAF V600E mutation in serous ovarian tumors: a comparative analysis of immunohistochemistry with a mutation-specific monoclonal antibody and allele-specific PCR.
    Bösmüller H; Fischer A; Pham DL; Fehm T; Capper D; von Deimling A; Bonzheim I; Staebler A; Fend F
    Hum Pathol; 2013 Mar; 44(3):329-35. PubMed ID: 23089489
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody.
    Capper D; Preusser M; Habel A; Sahm F; Ackermann U; Schindler G; Pusch S; Mechtersheimer G; Zentgraf H; von Deimling A
    Acta Neuropathol; 2011 Jul; 122(1):11-9. PubMed ID: 21638088
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of Molecular Methods and BRAF Immunohistochemistry (VE1 Clone) for the Detection of BRAF V600E Mutation in Papillary Thyroid Carcinoma: A Meta-Analysis.
    Parker KG; White MG; Cipriani NA
    Head Neck Pathol; 2020 Dec; 14(4):1067-1079. PubMed ID: 32358715
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The diagnostic utility of BRAF VE1 mutation-specific immunohistochemistry in ameloblastoma.
    Mendez LD; Wolsefer NS; Asa SL; Wasman J; Yoest JM; Stojanov IJ
    Mod Pathol; 2022 Nov; 35(11):1570-1577. PubMed ID: 35676332
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunohistochemistry with the anti-BRAF V600E (VE1) antibody: impact of pre-analytical conditions and concordance with DNA sequencing in colorectal and papillary thyroid carcinoma.
    Dvorak K; Aggeler B; Palting J; McKelvie P; Ruszkiewicz A; Waring P
    Pathology; 2014 Oct; 46(6):509-17. PubMed ID: 25014730
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunohistochemical detection of the BRAF V600E mutation in melanoma patients with monoclonal antibody VE1.
    Liu H; Li Z; Wang Y; Feng Q; Si L; Cui C; Guo J; Xue W
    Pathol Int; 2014 Dec; 64(12):601-6. PubMed ID: 25359093
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunohistochemical detection of the BRAF V600E mutant protein in colorectal neoplasms.
    Vakiani E; Yaeger R; Brooke S; Zhou Y; Klimstra DS; Shia J
    Appl Immunohistochem Mol Morphol; 2015 Jul; 23(6):438-43. PubMed ID: 25517872
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunohistochemistry for BRAF(V600E) antibody VE1 performed in core needle biopsy samples identifies mutated papillary thyroid cancers.
    Crescenzi A; Guidobaldi L; Nasrollah N; Taccogna S; Cicciarella Modica DD; Turrini L; Nigri G; Romanelli F; Valabrega S; Giovanella L; Onetti Muda A; Trimboli P
    Horm Metab Res; 2014 May; 46(5):370-4. PubMed ID: 24570209
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A mutant BRAF V600E-specific immunohistochemical assay: correlation with molecular mutation status and clinical outcome in colorectal cancer.
    Day F; Muranyi A; Singh S; Shanmugam K; Williams D; Byrne D; Pham K; Palmieri M; Tie J; Grogan T; Gibbs P; Sieber O; Waring P; Desai J
    Target Oncol; 2015 Mar; 10(1):99-109. PubMed ID: 24859797
    [TBL] [Abstract][Full Text] [Related]  

  • 35. VE1 Immunohistochemistry Improves the Limit of Genotyping for Detecting
    Choden S; Keelawat S; Jung CK; Bychkov A
    Cancers (Basel); 2020 Mar; 12(3):. PubMed ID: 32150939
    [TBL] [Abstract][Full Text] [Related]  

  • 36. BRAF VE1 immunoreactivity patterns in epithelioid glioblastomas positive for BRAF V600E mutation.
    Kleinschmidt-DeMasters BK; Aisner DL; Foreman NK
    Am J Surg Pathol; 2015 Apr; 39(4):528-40. PubMed ID: 25581727
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Assessment of BRAF V600E (VE1) protein expression and BRAF gene mutation status in codon 600 in benign and malignant salivary gland neoplasms.
    Bodnar M; Burduk P; Antosik P; Jarmuz-Szymczak M; Wierzbicka M; Marszalek A
    J Oral Pathol Med; 2017 May; 46(5):340-345. PubMed ID: 27682157
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Negative reactions of BRAF mutation-specific immunohistochemistry to non-V600E mutations of BRAF.
    Seto K; Haneda M; Masago K; Fujita S; Kato S; Sasaki E; Hosoda W; Murakami Y; Kuroda H; Horio Y; Hida T; Okubo K; Yatabe Y
    Pathol Int; 2020 May; 70(5):253-261. PubMed ID: 31970865
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Usefulness of immunohistochemistry for the detection of the BRAF V600E mutation in ovarian serous borderline tumors.
    Hayashi Y; Sasaki H; Takeshita S; Nishikawa R; Nishikawa H; Arakawa A; Yamashita Y; Takahashi S; Sugiura-Ogasawara M
    Oncol Rep; 2014 Nov; 32(5):1815-9. PubMed ID: 25174456
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diagnostic value of immunohistochemistry for the detection of the BRAF(V600E) mutation in papillary thyroid carcinoma: comparative analysis with three DNA-based assays.
    Ilie MI; Lassalle S; Long-Mira E; Bonnetaud C; Bordone O; Lespinet V; Lamy A; Sabourin JC; Haudebourg J; Butori C; Guevara N; Peyrottes I; Sadoul JL; Bozec A; Santini J; Capper D; von Deimling A; Emile JF; Hofman V; Hofman P
    Thyroid; 2014 May; 24(5):858-66. PubMed ID: 24417277
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.